Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Trust, London, UK.
Addiction. 2020 Mar;115(3):482-492. doi: 10.1111/add.14845. Epub 2019 Dec 12.
The use of cannabis has previously been linked to both depression and self-harm; however, the role of genetics in this relationship is unclear. This study aimed to estimate the phenotypic and genetic associations between cannabis use and depression and self-harm.
Cross-sectional data collected through UK Biobank were used to test the phenotypic association between cannabis use, depression and self-harm. UK Biobank genetic data were then combined with consortia genome-wide association study summary statistics to further test the genetic relationships between these traits using LD score regression, polygenic risk scoring and Mendelian randomization methods.
United Kingdom, with additional international consortia data.
A total of 126 291 British adults aged between 40 and 70 years, recruited into UK Biobank.
Phenotypic outcomes were life-time history of cannabis use (including initial and continued cannabis use), depression (including single-episode and recurrent depression) and self-harm. Genome-wide genetic data were used and assessment centre, batch and the first six principal components were included as key covariates when handling genetic data.
In UK Biobank, cannabis use is associated with an increased likelihood of depression [odds ratio (OR) = 1.64, 95% confidence interval (CI) = 1.59-1.70] and self-harm (OR = 2.85, 95% CI = 2.69-3.01). The strength of this phenotypic association is stronger when more severe trait definitions of cannabis use and depression are considered. Using consortia genome-wide summary statistics, significant genetic correlations are seen between cannabis use and depression [rg = 0.289, standard error (SE) = 0.036]. Polygenic risk scores for cannabis use and depression explain a small but significant proportion of variance in cannabis use, depression and self-harm within a UK Biobank target sample. However, two-sample Mendelian randomization analyses were not significant.
Cannabis use appeared to be both phenotypically and genetically associated with depression and self-harm. Limitations in statistical power mean that conclusions could not be made on the direction of causality between these traits.
先前有研究表明,大麻的使用与抑郁和自残有关;然而,遗传在这种关系中的作用尚不清楚。本研究旨在评估大麻使用与抑郁和自残之间的表型和遗传关联。
使用通过英国生物库收集的横断面数据来检验大麻使用、抑郁和自残之间的表型关联。然后,将英国生物库的遗传数据与联盟全基因组关联研究汇总统计数据相结合,使用 LD 得分回归、多基因风险评分和孟德尔随机化方法进一步检验这些特征之间的遗传关系。
英国,还有额外的国际联盟数据。
共有 126291 名年龄在 40 至 70 岁之间的英国成年人参加了英国生物库。
表型结果是终生大麻使用史(包括初始和持续的大麻使用)、抑郁(包括单次发作和复发性抑郁)和自残。使用全基因组遗传数据,并在处理遗传数据时包含评估中心、批次和前六个主成分作为关键协变量。
在英国生物库中,大麻使用与抑郁的可能性增加相关[比值比(OR)=1.64,95%置信区间(CI)=1.59-1.70]和自残(OR=2.85,95% CI=2.69-3.01)。当考虑更严重的大麻使用和抑郁特征定义时,这种表型关联的强度更强。使用联盟全基因组汇总统计数据,在大麻使用和抑郁之间观察到显著的遗传相关性[rg=0.289,标准误差(SE)=0.036]。大麻使用和抑郁的多基因风险评分在英国生物库目标样本内解释了大麻使用、抑郁和自残的一小部分但显著的方差。然而,两样本孟德尔随机化分析没有显著性。
大麻使用似乎与抑郁和自残既有表型又有遗传关联。统计能力的限制意味着不能就这些特征之间的因果关系方向得出结论。